Recently, systematic review and cross-sectional study revealed the notable increase of circulating TGF-β (a systemic immunosuppressor) levels in CFS patients [15,16]. This evidence concerns the gene TGFB1 and myalgic encephalomeyelitis/chronic fatigue syndrome.